Metoprolol and weight changes
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol and Weight Gain in Overweight and Diabetic Patients
Research shows that metoprolol, a commonly used beta-blocker, is associated with weight gain, especially in patients with type 2 diabetes and hypertension. In a large study, patients taking metoprolol tartrate gained an average of 1.19 kg over five months, while those on carvedilol did not experience significant weight changes. The weight gain with metoprolol was more pronounced in obese and morbidly obese patients compared to those on carvedilol, and this effect was not linked to changes in blood sugar, insulin resistance, or blood pressure control .
Metoprolol vs. Weight Reduction: Effects on Body Weight
Multiple randomized controlled trials in young, overweight patients with mild hypertension found that weight reduction through lifestyle changes led to significant weight loss (about 7–8 kg over 21 weeks), while metoprolol treatment did not result in weight loss. Instead, metoprolol was associated with either stable weight or slight weight gain. These studies also showed that weight reduction was more effective than metoprolol in improving blood pressure and reducing left ventricular mass, a marker of heart health 2356.
Metoprolol and Lipid Profile Changes
In addition to weight effects, metoprolol treatment was linked to a decrease in HDL (good) cholesterol and an increase in the total cholesterol to HDL ratio, which are considered adverse changes in lipid profile. In contrast, weight reduction improved cholesterol levels by lowering both total cholesterol and the total to HDL cholesterol ratio 23.
Metoprolol in Combination Therapy Across BMI Categories
A recent real-world study in patients with hypertension and stable coronary artery disease found that a fixed-dose combination of metoprolol, telmisartan, and chlorthalidone effectively reduced blood pressure across all BMI categories, including overweight and obese patients. The study did not specifically report on weight changes, but it showed that the combination therapy was well-tolerated and effective regardless of body weight .
Genetic Factors and Metoprolol Response in Obese Patients
Genetic differences can influence how patients with obesity respond to metoprolol. One study found that patients with a specific genetic variant (CYP2D6 1846G/A polymorphism) were more likely to experience increased body weight and side effects when treated with metoprolol succinate. Those with the GG genotype had better improvements in heart function and quality of life compared to those with the GA genotype .
Animal Studies: Metoprolol and Body Weight
In animal models, metoprolol did not significantly prevent body weight loss during illness, while a modified version of the drug (NO-metoprolol) was more effective in reducing weight loss and improving disease outcomes .
Conclusion
Metoprolol is associated with modest weight gain, particularly in overweight and diabetic patients, and may negatively affect cholesterol levels. Weight reduction through lifestyle changes is more effective for weight loss and improving heart health than metoprolol alone. Combination therapies with metoprolol can control blood pressure across different weight groups, but genetic factors may influence individual responses and side effects. For patients concerned about weight gain, alternative beta-blockers or lifestyle interventions may be preferable.
Sources and full results
Most relevant research papers on this topic